Vibegron 相關新聞

← 返回新聞總覽


Vibegron 目前有 0 則相關新聞報導,預測適應症 20 個。

本頁整合 Vibegron 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
  • 原適應症:Obgemsa is indicated in symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.
  • 證據等級:L5
  • 預測適應症(20 個):
    • overactive bladder (disease)(95.9%)
    • polycystic kidney disease 3 with or without polycystic liver disease(94.5%)
    • mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies(94.5%)
    • renal-hepatic-pancreatic dysplasia(92.5%)
    • Joubert syndrome with renal defect(91.5%)
    • thoracic malformation(91.3%)
    • esophageal varices with bleeding(91.3%)
    • esophageal varices without bleeding(91.3%)
    • karyomegalic interstitial nephritis(90.3%)
    • adult familial nephronophthisis-spastic quadriparesia syndrome(90.2%)
    • hypotrichosis simplex of the scalp(90.0%)
    • 16q24.1 microdeletion syndrome(89.0%)
    • congenital hypotrichosis milia(88.4%)
    • primary interstitial lung disease specific to childhood(88.4%)
    • isolated pulmonary capillaritis(88.0%)
    • congenital pulmonary lymphangiectasia(86.3%)
    • psychogenic movement disorders(85.6%)
    • chronic tic disorder(84.6%)
    • tremor-nystagmus-duodenal ulcer syndrome(84.1%)
    • primary orthostatic tremor(84.0%)

查看完整藥物報告 →

相關新聞(0 則)

目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。

免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.